• About us
• Contact

Advertisement

Organisation › Details

DuoCort Pharma AB

DuoCort Pharma is a drug development company focused on improving glucocorticoid therapy. The company has its origins among researchers at the Sahlgrenska University Hospital in Gothenburg and at Uppsala University in Sweden. DuoCort Pharma has developed Plenadren®, an improved glucocorticoid replacement therapy for patients with adrenal insufficiency, which is a rare disease. DuoCort Pharma has orphan drug designations in Europe and the USA for Plenadren. Plenadren is a once daily, dual-release hydrocortisone oral tablet. It has an outer layer that releases the drug immediately and an inner core that releases the drug over the day. The tablets come in both 5 mg and 20 mg strengths. *

 

	Start	2011-12-11 existent
	Group	Takeda (Group)
	Industry	Plenadren®
	Industry 2	DRUGS, ORPHAN
	Region	Helsingborg
	Country	Sweden
	Street	8 Kullagatan
	City	25220 Helsingborg
	Tel	+46-42-124020
		Address record changed: 2021-10-26
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2024-02-12

Advertisement

More documents for Takeda (Group)

• [1] AC Immune S.A.. (5/13/24). "Press Release: AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease". Osaka, Cambride, MA & Lausanne....
• [2] T-Curx GmbH. (8/28/23). "Press Release: T-Curx GmbH Announces Appointment of Two Industry Leaders to Its Board of Directors"....
• [3] Fresenius Medical Care AG & Co. KGaA. (12/5/22). "Press Release: Helen Giza to Take Over as Chief Executive Officer of Fresenius Medical Care"....
• [4] VectorY B.V.. (11/8/22). "Press Release: VectorY Appoints Sander van Deventer as CEO and Makes Key Appointments to Its Leadership Team". Amsterdam....
• [5] Heidelberg Pharma AG. (9/9/22). "Press Release: Heidelberg Pharma Announces Conclusion of License Agreement with Partner Takeda To Develop an Antibody Targeted Amanitin Conjugate". Ladenburg....
• [6] Takeda Pharmaceutical Co. Ltd.. (2/3/22). "Press Release: Takeda Announces Strategic Leadership Changes to Help Drive Continued Growth and Competitiveness in Global Marketplace". Osaka & Cambridge, MA....
• [7] Takeda Pharmaceutical Co. Ltd.. (1/10/22). "Press Release: Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (gd) T Cell Engager Therapies Targeting Solid Tumors". Osaka & London....
• [8] Integra Thepeutics S.L.. (12/2/21). "Press Release: Integra Tx Secures €4.5 Million in Funding from Advent France Biotechnology, Invivo Capital and Takeda Ventures". Barcelona....
• [9] GammaDelta Therapeutics Ltd.. (10/27/21). "Press Release: Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic gdT Cell Therapies Addressing Solid Tumors". Osaka & London....
• [10] Panekès Partners SGR S.p.A.. (9/27/21). "Press Release: Panakès Partners Appoints Dr. Rob Woodman as Partner to Lead Biotech Investment". Milan....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.